Arrowstreet Capital increased its stake in specialty chemical firm Innospec Inc. by 196.5% in Q1. This follows Innospec's strong quarterly earnings of $1.27 per share and 11.8% revenue growth, pushing
Allspring Global Investments Holdings LLC disclosed a 7.7% beneficial stake in Innospec Inc. via an amended Schedule 13G filing, holding 1,892,471 shares with sole voting and dispositive power.
Innospec Inc (IOSP) ranks 59th in the Chemicals industry with a valuation score of 6.12. Its current P/E ratio is 18.69, while other financial ratios remain undisclosed.
Argus Research raised its price target for Innospec Inc. (IOSP) to $90.00, as the chemical and fuel additive manufacturer trades at $84.95. The company operates through three distinct product segments
Dimensional Fund Advisors LP disclosed a 5.3% beneficial ownership stake in Innospec Inc., holding 1,305,038 shares as of June 30, 2026. The firm exercises sole voting power over most shares while dis
Innospec Inc. director Shelley J. Bausch filed an initial Form 3 insider ownership report with the SEC, establishing regulatory status with no reported share transactions.
Innospec Inc., a global specialty chemicals supplier, has been removed from the Russell 2000 Growth Benchmark and related indices. The company operates across Performance Chemicals, Fuel Specialties,
UBS Group AG sold 22,992 shares of Innospec Inc., reducing its stake by 13.9%. Innospec reported better-than-expected quarterly results with EPS of $1.05 and announced a $0.92 dividend despite analyst
Innospec Inc. raised its semi-annual dividend by 10% to $0.92 per share and launched a $75 million buyback program following Q1 2026 results. Capital returns continue despite ongoing margin and volume
Innospec reported FY 2025 net profit margin rebounded to 6.6% from 1.9%, driven by its specialty product focus. With analysts forecasting 12.8% annual earnings growth, the company has renewed a bullis
Vanguard Capital Management disclosed a 5.22% stake in Innospec Inc., holding over 1.3 million shares as of March 31, 2026, per a Schedule 13G filing indicating passive investment status.
Innospec Inc. exhibits high options volatility despite analyst Sell ratings and earnings downgrades, indicating potential trading divergences.
Analysts project Innospec (IOSP) earnings to fall 28.2% to $1.02/share and revenue to drop 2% to $432.15M for Q1 2026. A Zacks Rank of #4 signals uncertainty despite positive earnings ESP.
Vanguard Portfolio Management reported a 7.51% stake in Innospec Inc., holding 1,870,254 shares as of March 31, 2026. The SEC filing reveals Vanguard funds hold sole dispositive power over the equity.
ChemBrief